Cargando…
Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
Chimeric Antigen Receptor T (CAR-T) cell therapy has dramatically changed prognosis and treatment of relapsed and refractory hematologic malignancies. Currently the 6 FDA approved products target various surface antigens. While CAR-T therapy achieves good response, life-threatening toxicities have b...
Autores principales: | Mucha, Simon R., Rajendram, Prabalini |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217595/ https://www.ncbi.nlm.nih.gov/pubmed/37232836 http://dx.doi.org/10.3390/curroncol30050378 |
Ejemplares similares
-
Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021) -
A High Neutrophil-Lymphocyte Ratio Is Associated With Increased Morbidity and Mortality in Patients With Coronavirus Disease 2019
por: King, Alexander H., et al.
Publicado: (2021) -
Early and late complications of bariatric operation
por: Lim, Robert, et al.
Publicado: (2018) -
Risk factors associated with development of coinfection in critically Ill patients with COVID-19
por: Orsini, Erica M., et al.
Publicado: (2022) -
Early and late endocrine complications of COVID-19
por: Kazakou, Paraskevi, et al.
Publicado: (2021)